Natco Pharma gets US nod for Ondansetron

New Delhi, June 26 (UNI) Natco Pharma Ltd today said it has received the US Food and Drug Administration approval to market Ondansetron Hydrochloride tablets in multiple strengths in the United States.

The company aims to set up retail chains for Ondansetron, used in the treatment of nausea and vomiting caused by cancer treatments, in the US market.

This is its first FDA approval Natco, the drug maker said in a statement.

The tablets will be sold in the dosages of 4 mg and 8 mg, it added.

UNI